Tanzania Oncology Clinical Trials Market Analysis

Tanzania Oncology Clinical Trials Market Executive Summary

Tanzania's oncology clinical trials market is projected to grow from $5.06 Mn in 2022 to $8.31 Mn by 2030, registering a CAGR of 6.4% during the forecast period of 2022-30. Tanzania is home to the largest population in East Africa, with more than one-third of the population residing in the cities of Dar-es-Salaam, Mwanza, and Dodoma. Tanzania's high birth rate (35.3 births per 1,000 people), the high fertility rate (4.71 children per woman), and comparatively low life expectancy (61.6 years for males and 64.6 years for women) account for more than 60% of the population's age. As Tanzania moves closer to universal healthcare, the government has set aside $387.9 million for the health sector in 2020/2021, with $155.5 million going towards development projects to help the government execute its health-improving initiatives. Cancer is Tanzania's biggest non-communicable illness. Cervical cancer (25% of new cases in 2020), breast cancer (10%), and prostate cancer (9%). More than 26,000 people died from cancer in 2022.

Cancer is a major problem in the nation, with a high incidence of cervical, breast, and prostate cancer, among others. Because of the high occurrence of cancer, there is a chance to perform clinical trials and discover novel therapies. Efforts have been made in recent years to improve Tanzania's healthcare infrastructure and boost investment in research and development. To boost the country's research capacity, the government has developed research institutions and hospitals, as well as agreements with foreign organizations. The Tanzania Medicines and Medical Devices Authority (TMDA) and the Tanzania Commission for Science and Technology govern and supervise clinical research in Tanzania (COSTECH). Tanzania’s oncology clinical trials landscape is gradually evolving, with just a few clinical studies currently underway. Tanzania has a limited healthcare infrastructure, and the number of clinical trials done in the nation is low in comparison to other African countries.

Market Dynamics

Market Growth Drivers

One of the top reasons is the country's high cancer burden. Tanzania has high incidences of cervical, breast, and prostate cancer, among other cancers, which allows for clinical studies and the development of novel therapies. The country's rising expenditure on research and development boosts the country's research capacity, the government has developed research institutions and hospitals, as well as relationships with foreign organizations. Aga Khan Hospital Dar es Salaam, Bugando Medical Centre, Kilimanjaro Christian Medical Centre, and the Ocean Road Cancer Center are all major cancer treatment facilities. Also, foreign pharmaceutical firms are becoming interested in conducting clinical trials in Tanzania. This interest stems from the possibility of creating novel medicines and reaching a new patient group.

Market Restraints

Despite a population of 54 million people, Tanzania has fewer than 5 radiation treatment devices in commercial and governmental institutions combined as of 2020. There are also barely around 20 oncologists operating in Tanzania. Tanzanians also have one of the world's lowest rates of access to health professionals. Over 60% of Tanzania's healthcare facilities are operated by the government, with the remaining being faith-based or private. Such a lack of proper infrastructure, human resources, and finance are some of the factors that might stifle the progress of oncology clinical trials in Tanzania. Another impediment is the absence of clinical trial regulatory and ethical standards. To guarantee that clinical trials are done in an ethical and safe way, specific rules and regulations must be established. Furthermore, Tanzania's political and economic instability may be a barrier to the expansion of oncology clinical trials. These variables may have an effect on the availability of money and investment, as well as the recruitment and retention of participants in clinical trials.

Competitive Landscape

Key Players

• Pfizer Inc.
• Roche Holding AG
• Novartis International AG
• AstraZeneca plc
• Merck & Co., Inc.
• Eli Lilly and Company
• Sanofi S.A.
• Bristol Myers Squibb Company

Notable Insights

In December 2022, The Cancer Moonshot in a factsheet released additional steps to lower Africa’s cancer burden as part of the US - Africa leaders conference according to which:

The National Cancer Institute (NCI) has committed $48.5 Mn to assist HIV-Associated Malignancy Research Centers, which include several universities and scientists from the United States and throughout the African continent, including Tanzania.

With an initial financing commitment of more than $5 Mn, Global Health Catalyst will build a US-Africa Center of Excellence in Cancer Care, Research, and Teaching in Tanzania.

The American Childhood Cancer Organization offers financial assistance to identify hurdles to acquiring vital pediatric cancer treatments throughout East Africa, particularly Tanzania.